StreetInsider.com News Articles

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Wed, 26 Aug 2026 07:30:00 -0400

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough

Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC

NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Wed, 26 Aug 2026 07:30:00 -0400

Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC

NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Wed, 26 Aug 2026 07:30:00 -0400

Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC

NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Wed, 26 Aug 2026 07:30:00 -0400

Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC

NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for

Trevi Therapeutics (TRVI) PT Raised to $28 at Jones Trading

Thu, 13 Aug 2026 15:22:44 -0400

Jones Trading analyst Sean Kim raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $28.00 (from $24.00) while maintaining a Buy rating.

Trevi Therapeutics (TRVI) PT Raised to $30 at Cantor Fitzgerald

Fri, 07 Aug 2026 11:00:47 -0400

Cantor Fitzgerald analyst Josh Schimmer raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $30.00 (from $25.00) while maintaining a Overweight rating.

Trevi Therapeutics (TRVI) PT Raised to $25 at Oppenheimer

Fri, 07 Aug 2026 08:05:43 -0400

Oppenheimer analyst Leland Gershall raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $25.00 (from $24.00) while maintaining a Outperform rating.

Trevi Therapeutics (TRVI) PT Raised to $40 at Raymond James

Fri, 07 Aug 2026 06:25:59 -0400

Raymond James analyst Ryan Deschner raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $40.00 (from $27.00) while maintaining a Strong Buy rating.

The analyst comments "We remain Strong Buy rated on Trevi (TRVI) after a 2Q26 earnings print that included the announcement of the initiation of the pivotal Phase 3 program in IPF-CC (OCEAN-1 and 2) and the dose-finding Phase 2b study in RCC (LAKE) that were unveiled at the Investor & Analyst Day (recap HERE) earlier this year. Trevi also expects to initiate the first study for its new non-IPF ILD program, the Phase 2b portion of an

Trevi Therapeutics (TRVI) PT Raised to $40 at Raymond James

Fri, 07 Aug 2026 06:25:59 -0400

Raymond James analyst Ryan Deschner raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $40.00 (from $27.00) while maintaining a Strong Buy rating.

Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c

Thu, 06 Aug 2026 16:29:28 -0400

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

Form S-8 Trevi Therapeutics, Inc.

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884310.html

Form S-8 Trevi Therapeutics, Inc.

Thu, 06 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260806/26884310.html

Form 10-Q Trevi Therapeutics, Inc. For: Jun 30

Thu, 06 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26884148.html

Form 10-Q Trevi Therapeutics, Inc. For: Jun 30

Thu, 06 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26884148.html

Form 8-K Trevi Therapeutics, Inc. For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883845.html

Form 8-K Trevi Therapeutics, Inc. For: Aug 06

Thu, 06 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260806/26883845.html

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:05:00 -0400

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026

Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026

Management to host a conference call and webcast today at 4:30 p.m. ET 

NEW HAVEN, Conn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:05:00 -0400

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026

Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026

Management to host a conference call and webcast today at 4:30 p.m. ET 

NEW HAVEN, Conn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:05:00 -0400

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026

Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026

Management to host a conference call and webcast today at 4:30 p.m. ET 

NEW HAVEN, Conn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral

Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:05:00 -0400

Initiated Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter; Phase 3 OCEAN-2 trial expected to initiate in the third quarter of 2026

Initiated Phase 2b LAKE trial for patients with refractory chronic cough in the second quarter; sample size re-estimation expected in the fourth quarter of 2026

Management to host a conference call and webcast today at 4:30 p.m. ET 

NEW HAVEN, Conn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral

Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881429.html

Form SCHEDULE 13G/A Trevi Therapeutics, Inc. Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881429.html

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Thu, 30 Jul 2026 16:05:00 -0400

NEW HAVEN, Conn., July 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 6, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2026.

Conference Call and Webcast
To register for the

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Thu, 30 Jul 2026 16:05:00 -0400

Conference Call and Webcast
To register for the

Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

Thu, 30 Jul 2026 16:05:00 -0400

Conference Call and Webcast
To register for the